Cancer

Title Average Ratingsort descending
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary 50.00%
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. 50.00%
Roles of sildenafil in enhancing drug sensitivity in cancer. 50.00%
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in 50.00%
Ukrain treatment in a patient with non-seminomatous germ-cell tumour of testis (case report) 50.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Die Rolle von Boswellia-Säuren in der Therapie maligner Gliome: Methodische Mängel 50.00%
Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase 50.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. 50.00%
WITHDRAWN: Ovarian ablation for early breast cancer. 50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
Five novel mono-tetrahydrofuran ring acetogenins from the seeds of Annona muricata. 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. 50.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non 50.00%
Results of Ukrain monotherapy of prostate cancer 50.00%
Glioblastoma Multiforme 50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. 50.00%
Carbon-ion treatment 50.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
Role of everolimus in the treatment of renal cell carcinoma. 50.00%
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom 50.00%
An RF hyperthermia electrode which generates no edge effect. 50.00%
Cancer Prevention 50.00%
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosp 50.00%
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit 50.00%
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 50.00%
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer 50.00%
Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? 50.00%
Some pharmacological properties of prolonged administration of Ukrain in rodents 50.00%
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. 50.00%
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line 50.00%
Tumoral angiogenesis: review of the literature. 50.00%
Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin.... 50.00%
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study 50.00%
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother 50.00%
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
The story of the cancer medicine Ukrain and Wassil Nowicky 55.00%
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice 55.00%
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid 55.00%
Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. 55.00%
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). 55.00%
Pycnogenol may alleviate adverse effects in oncologic treatment. 60.00%
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and 60.00%
Systematic review of the treatment of cancer-associated anorexia and weight loss. 60.00%
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. 60.00%
Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angio.. 60.00%
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. 60.00%
Unconventional anticancer agents: a systematic review of clinical trials. 60.00%
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare 60.00%
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. 60.00%
Preliminary studies on the effect of Ukrain on the immunological response in patients with malignant tumours. 60.00%
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of 60.00%
Focal therapy for prostate cancer: revolution or evolution? 60.00%
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. 60.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. 60.00%
Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. 60.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ 60.00%
Strong synergy of heat and modulated electromagnetic field in tumor cell killing. 60.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer. 60.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Radiomodification effects of Ukrain, a cytostatic and immunomodulating drug, on intracellular glucocorticoid reception during sh 60.00%
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. 60.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m 60.00%
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate 60.00%
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. 60.00%
Boswellia 60.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... 60.00%
Survivin and pancreatic cancer. 60.00%
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. 60.00%
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer 60.00%
Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain in human tumour and normal cells 60.00%
Serum calcium and the risk of prostate cancer. 60.00%
Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. 60.00%
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. 60.00%
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect 60.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
Does the Ukrain preparation protect mice against lethal doses of bacteria? 60.00%
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky 60.00%
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status 60.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. 60.00%
Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marr 60.00%
Vitamin D and prostate cancer risk: a review of the epidemiological literature. 60.00%

Pages